Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 14,496 common shares on October 19, 2026, at a weighted-average price of $31.91 per share under a Rule 10b5-1 plan adopted June 2, 2026. The sales were executed in multiple trades at prices ranging from $31.67 to $32.53. The transactions included 8,580 shares held directly, 3,198 held by The Maetzold Descendants 2020 Trust, and 2,718 held by Derek Maetzold 2020 Irrevocable Trust. After the sales, reported holdings were 12,484 directly held shares, 4,840 shares in the Descendants trust, and 4,114 shares in the Irrevocable Trust.
Castle Biosciences, Inc. Chief Commercial Officer Tobin W. Juvenal sold 3,288 shares of common stock on October 12, 2026, at a reported weighted-average price of $33.64 per share. The sale was made under a Rule 10b5-1 plan adopted by Juvenal on May 28, 2026. After the transaction, he directly held 48,719 shares.
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal reported a proposed sale of 13,154 common shares, with an aggregate market value of $430,925.04. The notice lists October 12, 2026 as the approximate sale date. The sales are made in connection with a selling plan dated May 28, 2026, intended to comply with Rule 10b5-1(c).
Castle Biosciences Inc. CEO Derek J. Maetzold exercised 8,165 fully vested options at $2.39 per share for 8,165 common shares on October 5, 2026. Transactions included sales of 14,496 shares at a weighted-average $35.566 per share under a Rule 10b5-1 plan adopted June 2, 2026: 8,580 directly held by Maetzold, 3,198 held by The Maetzold Descendants 2020 Trust, and 2,718 by Derek Maetzold 2020 Irrevocable Trust. Those trusts reported 8,038 and 6,832 shares remaining, respectively.
Castle Biosciences, Inc. (CSTL) is identified as the issuer in a planned sale of 28,992 common shares for Officer Derek Maetzold’s account through Goldman Sachs & Co. LLC. The proposed sale has an aggregate market value of $1,062,556.8 and an approximate sale date of October 5, 2026.
The stated allocation is 17,160 shares by Derek Maetzold, 5,436 by DM 2020 Irrev Trust, and 6,396 by Maetzold Descendants 2020 Tr. The sales are connected to a selling plan dated June 2, 2026, intended to comply with Rule 10b5-1(c). Separate past-three-months transactions are also listed for Maetzold and named trusts.
Castle Biosciences Inc. Chief Operating Officer Kristen M. Oelschlager exercised fully vested options for 4,153 common shares on October 1, 2026, at a $3.38 exercise price, then sold 2,807 shares at a weighted-average $35.75 and 1,346 shares at a weighted-average $36.38. The transactions were made under a Rule 10b5-1 plan adopted March 17, 2026. Her indirect holdings included 72,649 common shares held by the Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries; the reported option position following the transaction was 8,305 shares.
Castle Biosciences Inc. (CSTL) lists a proposed sale by officer Kristen Oelschlager of 4,153 common shares, with Morgan Stanley Smith Barney LLC named as broker and October 1, 2026 as the approximate sale date. The related securities information gives an aggregate market value of $147,556.09 and describes the shares as tied to a cash exercise of stock options with the issuer.
Castle Biosciences (CSTL) Chief Commercial Officer Tobin W. Juvenal reported two direct sales of common stock: 5,543 shares on September 29, 2026, at a weighted-average price of $35.4980 per share, and 1,034 shares on September 30, 2026, at a weighted-average price of $34.2000 per share. Both sales were made pursuant to a Rule 10b5-1 plan adopted May 28, 2026. The September 29 trades were executed at prices ranging from $35.010 to $35.935, inclusive; the September 30 trades ranged from $34.090 to $34.525, inclusive.
Castle Biosciences Inc. (CSTL) President and CEO Derek J. Maetzold exercised fully vested options for 8,580 common shares on September 21, 2026, at an exercise price of $2.39 per share, then sold those shares at a weighted-average $35.334 per share. The Maetzold Descendants 2020 Trust sold 3,198 shares and the Derek Maetzold 2020 Irrevocable Trust sold 2,718 shares, each at the same weighted-average price. The transactions were made under a Rule 10b5-1 plan adopted June 2, 2026.
CASTLE BIOSCIENCES INC (CSTL) disclosed that Chief Commercial Officer Juvenal Tobin sold company common stock in two open-market transactions reported on Form 4. On September 14, 2026 he sold 3,306 shares at a weighted-average price of $32.324 per share, and on September 15, 2026 he sold 3,294 shares at a weighted-average price of $35.142 per share. Both sales were made pursuant to a Rule 10b5-1 plan adopted on May 28, 2026, and each was executed in multiple trades within stated price ranges.